Study of TP-3654 in Patients With Advanced Solid Tumors

Advanced Solid Tumors Clinical Trial

Official title:

A Phase I, First-in-human, Open-label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients With Advanced Solid Tumors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03715504
• Other study ID #: TP-3654-101
• Status: Completed
• Phase: Phase 1
• Start date: April 16, 2019
• Est. completion date: July 8, 2021

Study information

• Verified date: November 2023
• Source: Sumitomo Pharma America, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

TP-3654 is an oral PIM inhibitor. This is a Phase 1, open-label, dose-escalation, safety, pharmacokinetics, and pharmacodynamic study, with a purpose of determining the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of oral TP-3654 in patients with advanced solid tumors.

Description:

Primary Objective:

• To determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of oral TP-3654 in patients with advanced solid tumors.

Secondary Objectives:

• To establish the pharmacokinetic (PK) profile of orally administered TP-3654

• To observe patients for any evidence of antitumor activity of TP-3654 by objective radiographic assessment

• To study the pharmacodynamic effects of TP-3654 therapy

• To establish the Recommended Phase 2 Dose (RP2D) for future studies with TP-3654

Recruitment information / eligibility

• Status: Completed
• Enrollment: 22
• Est. completion date: July 8, 2021
• Est. primary completion date: March 30, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• 1. Have a histologically confirmed diagnosis of advanced metastatic, progressive or unresectable solid tumor

2. Be refractory to, or intolerant of, established therapy known to provide clinical benefit for their condition.

3. Have 1 or more tumors measurable or evaluable as outlined by modified Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

4. Have an Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to 2

5. Have a life expectancy greater than or equal to 3 months

6. Be greater than or equal to 18 years of age

7. Have a negative pregnancy test (if female of childbearing potential) and not currently nursing

8. Have acceptable liver function:

a. Bilirubin less than or equal to 1.5x upper limit of normal (ULN) (unless associated with Gilbert's syndrome b. Aspartate aminotransferase (AST/SGOT), alanine aminotransferase (ALT/SGPT) and alkaline phosphatase less than or equal to 2.5x upper limit of normal (ULN) *If liver metastases are present, then less than or equal to 5x ULN is allowed.

9. Have acceptable renal function:

a. Calculated creatinine clearance greater than or equal to 30 mL/min

10. Have acceptable hematologic status:

a. Absolute Neutrophil Count (ANC) greater than or equal to 1500 x10^9/L b. Platelet count greater than or equal to 100,000 x 10^9/L c. Hemoglobin greater than or equal to 8 g/dL

11. Have acceptable coagulation status:

1. Prothrombin time (PT) within 1.5 x normal limits

2. Activated partial thromboplastin time (aPTT) within 1.5 x normal limits

12. Be nonfertile or agree to use an adequate method of contraception. Sexually active patients and their partners must use an effective method of contraception (hormonal or barrier method of birth control; or abstinence) prior to study entry and for the duration of study participation and for 3 months (males) and 6 months (females) after the last study drug dose. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.

13. Have read and signed the Institutional Review Board (IRB)-approved informed consent form prior to any study related procedure. (In the event that the patient is re-screened for study participation or a protocol amendment alters the care of an ongoing patient, a new informed consent form must be signed.)

Exclusion Criteria:

• 1. History of congestive heart failure (CHF), Cardiac disease, myocardial infarction within the past 6 months prior to Cycle 1 Day 1, left ventricular ejection fraction <45% by echocardiogram, unstable arrhythmia, or evidence of ischemia on electrocardiogram (ECG) within 14 days prior to Cycle 1 Day 1

2. Have a corrected QT interval (using Fridericia's correction formula) (QTcF) of >450 msec in men and >470 msec in women

3. Presence of symptomatic central nervous system metastatic disease or disease that requires local therapy such as radiotherapy, surgery, or increasing dose of steroids within the prior 2 weeks.

4. Have severe chronic obstructive pulmonary disease with hypoxemia (defined as resting 02 saturation of less than or equal to 90% breathing room air). The use of supplemental oxygen with nasal cannula to reach >90% saturation will not preclude study participation.

5. Have undergone major surgery, other than diagnostic surgery, within 2 weeks prior to Cycle 1 Day 1

6. Have active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy

7. Received treatment with radiation therapy, surgery, chemotherapy, or investigational therapy within 28 days or 5 half-lives, whichever occurs first, prior to study entry (6 weeks for nitrosoureas or Mitomycin C)

8, Are unwilling or unable to comply with procedures required in this protocol

9. Have known infection with human immunodeficiency virus, hepatitis B, or hepatitis C. Patients with history of chronic hepatitis that is currently not active are eligible.

10. Have a serious nonmalignant disease (eg, hydronephrosis, liver failure, or other conditions) that could compromise protocol objectives in the opinion of the Investigator and/or the Sponsor

11. Are currently receiving any other investigational agent

12. Have exhibited allergic reactions to a similar structural compound, biological agent, or formulation

13. Have a medical conditional such as Crohn's disease or have undergone significant surgery to the gastrointestinal tract that could impair absorption or that could result in short bowel syndrome with diarrhea due to malabsorption.

Related Conditions & MeSH terms

• Advanced Solid Tumors
• Neoplasms

Intervention

Drug:
• TP-3654
oral PIM inhibitor

Locations

Country	Name	City	State
United States	University of Virginia	Charlottesville	Virginia
United States	MD Anderson	Houston	Texas
United States	Huntsman Cancer Institute	Salt Lake City	Utah

Sponsors (1)

Lead Sponsor	Collaborator
Sumitomo Pharma America, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of dose-limiting toxicities (DLTs) and treatment emergent adverse events		28 days
Primary	Determine maximum tolerated dose (MTD)	MTD will be determined based upon toxicity grades which are defined by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE).	20 months
Secondary	Recommended Phase 2 Dose of TP-3654	To establish the Recommended Phase 2 Dose (RP2D) for future studies with TP-3654, MTD data to be reviewed	23 months
Secondary	Determine antitumor activity of TP-3654	Assess for tumor burden by radiological assessment (computed tomography [CT] imaging) using RECIST v1.1	20 months